Drug interaction classified as: antagonism
Source: DDInter
Rapid-acting insulin analogue · Antidiabetic

KDIGO 2024 + manufacturer label
7 branded formulations and 8 fixed-dose combinations. Look up specific brands in the Drugs workspace.
Recombinant insulin analogue (Lys-B28, Pro-B29 reversal) reducing self-association → faster SC absorption and rapid, short prandial insulin-receptor agonism; mimics physiological mealtime insulin.
Acceptable in pregnancy when prandial insulin needed — commonly used; titrate to targets
Compatible — not orally bioavailable to infant; adjust maternal dose
Drug interaction classified as: antagonism
Source: DDInter
Drug interaction classified as: antagonism.
Source: DDInter
Clinical effect not specified
Source: DDInter
Clinical effect not specified
Source: DDInter
Clinical effect not specified
Source: DDInter
Clinical effect not specified
Source: DDInter
Clinical effect not specified
Source: DDInter
.
Source: DDInter
Clinical effect not specified
Source: DDInter
.
Source: DDInter
Clinical effect not specified
Source: DDInter
Clinical effect not specified
Source: DDInter
Continue into a citation-backed clinical answer with the drug context already attached.
Sources: Goodman & Gilman 14e, Katzung, BNF·Verified: 2026-05-19 · House clinical team·Cockpit curated: 2026-05-19